Health Technology Assessment: Using Biostatistics to Break the Barriers of Adopting New Medicines - Image 1

£95.00

CRC Press Health Technology Assessment: Using Biostatistics to Break the Barriers of Adopting New Medicines

Name: Health Technology Assessment: Using Biostatistics to Break the Barriers of Adopting New Medicines
Brand: CRC Press
Price: 95.0 GBP
Availability: InStock

Biological Sciences

It has never been this cheap. We have no record of a lower price.

£95 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 73 days · 73 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 73 days • 1 price levels

Days at Price

Price Analysis

Most common price: £95 (73 days, 100.0%)

Price range: £95 - £95

Price levels: 1 different prices over 73 days

Description

The term health technology refers to drugs, devices, and programs that can improve and extend quality of life. As decision-makers struggle to find ways to reduce costs while improving health care delivery, health technology assessments (HTA) provide the evidence required to make better-informed decisions. This is the first book that focuses on the statistical options of HTAs, to fully capture the value of health improvements along with their associated economic consequences. After reading the book, readers will better understand why some health technologies receive regulatory or reimbursement approval while others do not, what can be done to improve the chances of approval, as well as common shortcomings of submissions for drug and device reimbursement. The book begins by contrasting the differences between regulatory approval and reimbursement approval. Next, it reviews the principles and steps for conducting an HTA, including the reasons why different agencies will have a different focus for their scope in the HTA. Supplying an accessible introduction to the various statistical options for different methods in an HTA, the book identifies the links to regulatory and reimbursement decisions for each option. It highlights many of the methodological advances that have occurred since HTA research began, to provide researchers and decision-makers with a cutting-edge framework. It also details the logical basis for the methods along with simple instructions on how to conduct the various techniques. Both authors have considerable experience in generating evidence for submissions and reviewing submissions to decision-makers for funding. One of the authors has also received a nationally recognized lifetime achievement award in this area.

Product Specifications

Brand: CRC Press
Format: hardcover
ASIN: 1482244527
Category: Books > Subjects > Science, Nature & Maths > Biological Sciences
Domain: Amazon UK
Release Date: 10 April 2015
Listed Since: 15 September 2014

Barcode

No barcode data available

CRC Press Health Technology Assessment: Using Biostatistics to Break the Barriers of Adopting New Medicines

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects (Chapman & Hall/CRC Biostatistics Series)

Real-World Evidence in a Patient-Centric Digital Era (Chapman & Hall/CRC Biostatistics Series)

Real-World Evidence in a Patient-Centric Digital Era (Chapman & Hall/CRC Biostatistics Series)

Design and Analysis of Clinical Trials: Concept and Methodologies (Wiley Series in Probability and Statistics)

Translational Research in Biomedical Sciences: Recent Progress and Future Prospects

Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials (Chapman & Hall/CRC Biostatistics Series)

Comparative Effectiveness Research in Health Services (Health Services Research)

Translational Medicine: Strategies and Statistical Methods: 28 (Chapman & Hall/CRC Biostatistics)

Multiregional Clinical Trials for Simultaneous Global New Drug Development (Chapman & Hall/CRC Biostatistics Series)

Artificial Intelligence in Drug Development: Patenting and Regulatory Aspects (Frontiers of Artificial Intelligence, Ethics and Multidisciplinary Applications)

Patient Involvement in Health Technology Assessment (Health Informatics)

Clinical Trial Data Analysis Using R and SAS (Chapman & Hall/CRC Biostatistics Series)

Patient Involvement in Health Technology Assessment

Clinical Trial Data Analysis Using R and SAS (Chapman & Hall/CRC Biostatistics Series)

Clinical Trial Biostatistics and Biopharmaceutical Applications

The Advanced Handbook of Methods in Evidence Based Healthcare

A Concise Guide to Clinical Trials

Practical Considerations for Adaptive Trial Design and Implementation (Statistics for Biology and Health)

Science in Medicine: From Authoritative Opinion through Evidence-Based Medicine to Big Data & Beyond (New Developments in Medical Research)

Clinical Research Law and Ethics: Human Research and a Complete Practical Guide to Regulatory Compliance

Personalized Medicine in Healthcare Systems: Legal, Medical and Economic Implications: 5 (Europeanization and Globalization, 5)

Jones & Bartlett Evidence-Based Practice for Health Professionals

Design & Analysis of Clinical Trials for Economic Evaluation & Reimbursement: An Applied Approach Using SAS & STATA: 87 (Chapman & Hall/CRC Biostatistics Series)

The Future Circle of Healthcare: AI, 3D Printing, Longevity, Ethics, and Uncertainty Mitigation (Future of Business and Finance)